Showing 2721-2730 of 5802 results for "".
- Five ASDS Members Receive President's Awards at Annual Meetinghttps://practicaldermatology.com/news/five-asds-members-receive-presidents-awards-at-annual-meeting/2458024/Five members of the American Society for Dermatologic Surgery (ASDS) received President’s Awards for their contributions to the Society and dermatologic specialty at the 2017 ASDS Annual Meeting in Chicago. The 2017 recipients were Murad Alam, MD,
- Meet Thermage's New FLX Systemhttps://practicaldermatology.com/news/meet-thermages-new-flxtm-system/2458026/The US Food and Drug Administration granted 510(K) clearance to Solta Medical’s new Thermage FLXTM System for smoothing skin on the face, eyes, and body. The Thermage FLX features a new optimized energy delivery algorithm, know
- FDA Adds Third Approved Indication for Botox Cosmetic: Forehead Lineshttps://practicaldermatology.com/news/fda-adds-third-approved-indication-for-botox-cosmetic-forehead-lines/2458032/Allergan plc's Botox Cosmetic received ts third FDA indication—the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults. This approval makes the brand the first and only neurotoxin indicated for three facial tre
- Castle Creek Pharmaceuticals Unveils First-Ever IGA Scale for EBS Clinical Researchhttps://practicaldermatology.com/news/castle-creek-pharmaceuticals-unveils-first-ever-iga-scale-for-ebs-clinical-research/2458035/Castle Creek Pharmaceuticals (CCP) has developed and validated the first Investigator's Global Assessment (IGA) scale to be used by clinicians evaluating the average overall severity of epidermolysis bullosa simplex (EBS) lesions in clinical tria
- FDA Clears Fotona's StarWalker MaQX Ultra Performance Q-Switched Systemhttps://practicaldermatology.com/news/fda-clears-fontinas-starwalker-maqx-ultra-performance-q-switched-system/2458038/The FDA has cleared Fotona's StarWalker MaQX Q-Switched laser system for treating tattoos, pigmented and vascular lesions, acne and scar revision, and permanent hair reduction. The Verde 532 mode in a "tattoo laser" is exclusive to the MaQX. Sales in the US will begin immediately. T
- Update from DFB Soria on Enrollment in Phase 2 Clinical Trial of Nanoparticle Paclitaxel Ointment for AKhttps://practicaldermatology.com/news/update-from-dfb-soria-on-enrollment-in-phase-2-clinical-trial-of-nanoparticle-paclitaxel-ointment-for-ak/2458039/DFB Soria, a clinical-stage pharmaceutical development company, and an affiliate of NanOlogy™, completed the second of four patient cohorts enrolled in a Phase 2 actinic keratosis (AK) clinical trial of a topical ointment containing nanoparticle
- Novan Has Guidance Meeting with FDA on SB204https://practicaldermatology.com/news/novan-has-guidance-meeting-with-fda-on-sb204/2458040/Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which the agency advised that an additional pivotal trial should be conducted. Given the need for the ad
- New Data: Aclaris' A-101 40% Safely Banishes Facial SK Lesionshttps://practicaldermatology.com/news/new-data-aclaris-a-101-40-safely-banishes-facial-sk-lesions/2458044/Good news for Aclaris. New data suggest that their drug candidate A-101 40 percent may be an appealing option to remove seborrheic keratosis (SK) lesions in highly visible areas, such as the face, with minimal risk of s
- Five-Year Data Show Sustained Efficacy, Safety for Cosentyxhttps://practicaldermatology.com/news/five-year-data-show-sustained-efficacy-safety-for-cosentyx/2458054/Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase III data. These data were presented for
- FDA Accepts NDAs for Review of Binimetinib And Encorafenib for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-accepts-ndas-for-review-of-binimetinib-and-encorafenib-for-advanced-braf-mutant-melanoma/2458058/The FDA has accepted Array BioPharma's New Drug Applications (NDAs) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The FDA se